| Name | Title | Contact Details |
|---|---|---|
Alethia Young |
Chief Financial Officer | Profile |
Julia Tran |
Chief People Officer | Profile |
Sandra Manrriquez |
Associate Director, People Operations and Total Rewards | Profile |
Daisy Leung |
Vice President, Product Strategy and Development | Profile |
AnHeart is a clinical stage global biopharmaceutical company developing novel precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need.
Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Biochrom is a Holliston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CTMG is a Greenville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.